12:00 AM
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Epratuzumab: Phase II data

The international Phase II COG-ADVL04P2 trial in 116 patients aged 2-30 with early bone marrow relapse of B cell precursor ALL showed that chemotherapy plus epratuzumab missed the primary endpoint of a >=13% improvement in the rate of second complete remission compared to a 67% rate of second complete remission for...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >